Small molecule mimetics of Humanin that normalize neuronal p-Akt as novel therapeutics for AD

护脑素小分子模拟物可使神经元 p-Akt 正常化,作为 AD 的新型疗法

基本信息

  • 批准号:
    10810521
  • 负责人:
  • 金额:
    $ 27.48万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-04-01 至 2024-03-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT (Supplement) Humanin (HN), a 24-amino acid mitochondrial-derived peptide from the occipital lobe of postmortem sporadic AD patient brain tissue [1] is a neuroprotective peptide that could protect neurons from Aβ-related and NMDA- induced toxicity [2]. A decrease in the endogenous HN plasma level with age has been reported [3], and decreased HN levels has been linked to cognitive decline during aging. The identification of a SNP (rs2854128) using mitochondrial GWAS in the HN-coding region of the mitochondrial genome from a large sample of older adults further supports the role of HN and its circulating levels with accelerated cognitive decline [4]. The availability of high throughput screening (HTS) formattable assays, allow for screening to identify small molecules that can enhance HN expression and its levels in AD models. In the parent grant we completed screening for small molecules that act as humanin (HN) mimetics and have identified validated hits that increase both the p- gp130 and p-Akt levels in neuronal cells. Further analoging, testing and evaluation of these mimetics are ongoing following the path outlined in the grant. The availability of new assays to assess levels of HN peptide itself in vitro and in tissue has presented the opportunity to also identify small molecules that enhance HN levels. Our preliminary data using this assay shows that we can detect HN levels in SH-SY5Y cells. Hence for the Supplement research we propose is to conduct screening for HN enhancers using the human neuroblastoma SH-SY5Y cells that express and secrete HN [5]. The work we propose in the Supplement is directed toward formatting of the available HN ELISA assay for HTS and screening of a subset of the UCLA compound library to identify compounds that change HN levels in cells. Hits from the screening would be validated and then undergo secondary testing to confirm HN enhancement in SH-SY5Y and iPSC-derived human neurons, as well as in murine neuroblastoma N2a. Validated hits would also be assessed for increasing neuronal p-Akt. Thus, in the supplement we propose an Expansion of Aim1 of the parent grant to include identification of HN enhancers that along with our currently identified HN mimetics would undergo further testing and evaluation as outlined in the parent grant. Hits from the screening would then undergo secondary testing to confirm HN enhancement in SH-SY5Y and iPSC-derived human neurons, as well as in murine neuroblastoma N2a cells. Validated hits would also be assessed using our p-Akt AlphaLISA to confirm biological activity in neurons. Validated HN enhancers would undergo prioritization as part of Expansion of Aim3 of the parent grant by evaluation in in vitro ADME-T assays. Prioritized analogs would undergo pharmacokinetic (PK) and pharmacodynamics (PD) studies to identify brain permeable HN enhancers. Such an HN enhancers identified from the supplement grant would have the potential to be developed as novel therapeutic candidates for Alzheimer's disease (AD), and could in the future also be evaluated in other disorders such as diabetes and cardiovascular disease.
摘要(补充) 护脑素 (HN),一种来自死后散发性枕叶的 24 个氨基酸线粒体衍生肽 AD 患者脑组织 [1] 是一种神经保护肽,可以保护神经元免受 Aβ 相关和 NMDA- 的影响 诱导毒性[2]。据报道,内源性 HN 血浆水平随着年龄的增长而下降 [3],并且 HN 水平下降与衰老过程中认知能力下降有关。 SNP 的鉴定 (rs2854128) 在来自老年人的大量样本的线粒体基因组的 HN 编码区中使用线粒体 GWAS 成年人进一步支持 HN 及其循环水平加速认知衰退的作用 [4]。这 高通量筛选 (HTS) 格式分析的可用性,允许筛选以识别小分子 可以增强 AD 模型中 HN 的表达及其水平。在家长补助金中,我们完成了筛选 充当护脑素 (HN) 模拟物的小分子,并已鉴定出可增加 p- 的经过验证的命中 神经元细胞中的 gp130 和 p-Akt 水平。对这些模拟物的进一步模拟、测试和评估正在进行中 遵循拨款中概述的路径。评估 HN 肽本身水平的新测定方法的可用性 体外和组织内也提供了鉴定增强 HN 水平的小分子的机会。我们的 使用该测定的初步数据表明我们可以检测 SH-SY5Y 细胞中的 HN 水平。因此对于 我们建议的补充研究是利用人神经母细胞瘤筛选 HN 增强剂 表达和分泌 HN 的 SH-SY5Y 细胞 [5]。我们在补编中提出的工作旨在 对 HTS 可用的 HN ELISA 测定进行格式化,并筛选 UCLA 化合物库的子集,以 识别改变细胞中 HN 水平的化合物。筛选中的命中将得到验证,然后进行 二次测试以确认 SH-SY5Y 和 iPSC 衍生的人类神经元以及 小鼠神经母细胞瘤 N2a。还将评估经验证的命中是否增加神经元 p-Akt。因此,在 补充,我们建议扩大母基金的目标1,以包括 HN 增强剂的鉴定 与我们目前确定的 HN 模拟物一起将接受进一步的测试和评估,如 家长补助金。筛选后的命中将进行二次测试,以确认 HN 在 SH-SY5Y 和 iPSC 衍生的人类神经元,以及鼠神经母细胞瘤 N2a 细胞。经验证的点击将 还可以使用我们的 p-Akt AlphaLISA 进行评估,以确认神经元的生物活性。经验证的 HN 增强剂 将通过体外 ADME-T 评估作为母基金 Aim3 扩展的一部分进行优先排序 化验。优先的类似物将接受药代动力学 (PK) 和药效学 (PD) 研究,以确定 脑渗透性 HN 增强剂。从补充补助金中确定的此类 HN 增强剂将具有 有潜力被开发为阿尔茨海默病(AD)的新型治疗候选药物,并且在未来可能 还可对糖尿病和心血管疾病等其他疾病进行评估。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Varghese John其他文献

Varghese John的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Varghese John', 18)}}的其他基金

Evaluating the p-Tau inhibition and neuroprotective effects of sAPPalpha using brain permeable small molecules
使用脑通透性小分子评估 sAPPalpha 的 p-Tau 抑制和神经保护作用
  • 批准号:
    10522638
  • 财政年份:
    2022
  • 资助金额:
    $ 27.48万
  • 项目类别:
Screening for Compounds that Lower Intracellular Alpha-Synuclein Levels
筛选降低细胞内 α-突触核蛋白水平的化合物
  • 批准号:
    10218979
  • 财政年份:
    2021
  • 资助金额:
    $ 27.48万
  • 项目类别:
Screening for enhancers of secreted clusterin (sCLU) and evaluation in AD models
分泌型凝聚素 (sCLU) 增强子的筛选和 AD 模型的评估
  • 批准号:
    10195566
  • 财政年份:
    2021
  • 资助金额:
    $ 27.48万
  • 项目类别:
Small molecule mimetics of Humanin that normalize neuronal p-Akt as novel therapeutics for AD
护脑素小分子模拟物可使神经元 p-Akt 正常化,作为 AD 的新型疗法
  • 批准号:
    10211023
  • 财政年份:
    2021
  • 资助金额:
    $ 27.48万
  • 项目类别:
Screening for Compounds that Lower Intracellular Alpha-Synuclein Levels
筛选降低细胞内 α-突触核蛋白水平的化合物
  • 批准号:
    10524695
  • 财政年份:
    2021
  • 资助金额:
    $ 27.48万
  • 项目类别:
ApoE4-targeted therapeutics that normalize SirT1
使 SirT1 正常化的 ApoE4 靶向疗法
  • 批准号:
    9914435
  • 财政年份:
    2019
  • 资助金额:
    $ 27.48万
  • 项目类别:
Screening for enhancers of sAPPalpha
筛选 sAPPalpha 增强子
  • 批准号:
    9038682
  • 财政年份:
    2016
  • 资助金额:
    $ 27.48万
  • 项目类别:
Screening for enhancers of sAPPalpha
筛选 sAPPalpha 增强子
  • 批准号:
    9265756
  • 财政年份:
    2016
  • 资助金额:
    $ 27.48万
  • 项目类别:
ApoE4-targeted therapeutics that normalize SirT1
使 SirT1 正常化的 ApoE4 靶向疗法
  • 批准号:
    8988211
  • 财政年份:
    2015
  • 资助金额:
    $ 27.48万
  • 项目类别:
ApoE4-targeted therapeutics that normalize SirT1
使 SirT1 正常化的 ApoE4 靶向疗法
  • 批准号:
    9231359
  • 财政年份:
    2015
  • 资助金额:
    $ 27.48万
  • 项目类别:

相似海外基金

A Longitudinal Qualitative Study of Fentanyl-Stimulant Polysubstance Use Among People Experiencing Homelessness (Administrative supplement)
无家可归者使用芬太尼兴奋剂多物质的纵向定性研究(行政补充)
  • 批准号:
    10841820
  • 财政年份:
    2023
  • 资助金额:
    $ 27.48万
  • 项目类别:
Proton-secreting epithelial cells as key modulators of epididymal mucosal immunity - Administrative Supplement
质子分泌上皮细胞作为附睾粘膜免疫的关键调节剂 - 行政补充
  • 批准号:
    10833895
  • 财政年份:
    2023
  • 资助金额:
    $ 27.48万
  • 项目类别:
Administrative Supplement: Life-Space and Activity Digital Markers for Detection of Cognitive Decline in Community-Dwelling Older Adults: The RAMS Study
行政补充:用于检测社区老年人认知衰退的生活空间和活动数字标记:RAMS 研究
  • 批准号:
    10844667
  • 财政年份:
    2023
  • 资助金额:
    $ 27.48万
  • 项目类别:
StrokeNet Administrative Supplement for the Funding Extension
StrokeNet 资助延期行政补充文件
  • 批准号:
    10850135
  • 财政年份:
    2023
  • 资助金额:
    $ 27.48万
  • 项目类别:
2023 NINDS Landis Mentorship Award - Administrative Supplement to NS121106 Control of Axon Initial Segment in Epilepsy
2023 年 NINDS 兰迪斯指导奖 - NS121106 癫痫轴突初始段控制的行政补充
  • 批准号:
    10896844
  • 财政年份:
    2023
  • 资助金额:
    $ 27.48万
  • 项目类别:
Biomarkers of Disease in Alcoholic Hepatitis Administrative Supplement
酒精性肝炎行政补充剂中疾病的生物标志物
  • 批准号:
    10840220
  • 财政年份:
    2023
  • 资助金额:
    $ 27.48万
  • 项目类别:
Administrative Supplement: Improving Inference of Genetic Architecture and Selection with African Genomes
行政补充:利用非洲基因组改进遗传结构的推断和选择
  • 批准号:
    10891050
  • 财政年份:
    2023
  • 资助金额:
    $ 27.48万
  • 项目类别:
Power-Up Study Administrative Supplement to Promote Diversity
促进多元化的 Power-Up 研究行政补充
  • 批准号:
    10711717
  • 财政年份:
    2023
  • 资助金额:
    $ 27.48万
  • 项目类别:
Administrative Supplement for Peer-Delivered and Technology-Assisted Integrated Illness Management and Recovery
同行交付和技术辅助的综合疾病管理和康复的行政补充
  • 批准号:
    10811292
  • 财政年份:
    2023
  • 资助金额:
    $ 27.48万
  • 项目类别:
Administrative Supplement: Genome Resources for Model Amphibians
行政补充:模型两栖动物基因组资源
  • 批准号:
    10806365
  • 财政年份:
    2023
  • 资助金额:
    $ 27.48万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了